Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma
Safety in Asthma Patients
This is a phase 1 study, randomized, double-blind, placebo-controlled, 2 treatment, 2 period crossover study to evaluate the pharmacokinetics, safety, and tolerability of a single inhaled dose of ASY202 in adults with stable asthma.
Following screening, eligible participants will be enrolled and randomized to one of two treatment sequences. Participants will receive a single inhaled dose of ASY202 and a single inhaled dose of placebo, each administered once during separate study periods.
During each treatment period, subjects will have an on-site visit in the clinical research unit for dosing, safety monitoring and PK assessments, including serial blood sampling, spirometry, vital signs, clinical laboratory tests, and ECGs. A call 24 hours after dosing is scheduled to follow up for safety.
Participants will return for their next treatment period after a washout interval to ensure complete clearance of study medication. All subjects will receive both treatments over the course of the study.
A follow-up/end of study call will occur around 8 days after the last dose to assess ongoing safety and tolerability.